Hospitals have not seen decreases in prices of Valeant heart medications
Some of the top heart hospitals in the country have not received price breaks on two drugs manufactured by Valeant Pharmaceuticals, the New York Times reports.
Valeant testified in front of Congress on May 4 and said it would offer hospitals as much as a 30 percent discount on nitropress and isuprel, two commonly prescribed medications for heart patients. However, administrators at the Cleveland Clinic, Mayo Clinic, Johns Hopkins and New York-Presbyterian told the New York Times that the prices of the expensive medications have not changed.
Read more at the link below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.